The results of a clinical trial suggest that a new drug slows the functional decline seen in patients with mild Alzheimer’s disease, according to a report in the online issue of The Lancet Neurology. The drug is called tarenflurbil, which is an agent that selectively and safely lowers amyloid-beta-42, which form amyloid. The major characteristic of the disease is the formation of amyloid plaques in the brain, which are the target of most Alzheimer’s disease therapies. This is “the first, or one

More: continued here